Medaica Deploys AI Home Heart Exam Kit

The Las Vegas Review-Journal reported June 14, 2026, that Medaica, a Henderson, Nevada digital health startup, is marketing a home heart exam kit bundling a patented digital stethoscope, a guided telehealth heart exam, AI-assisted cardiologist review, and a cardiac report. CEO Stephen Randall described the product's goal as reducing the number of undiagnosed heart disease patients. The story includes photographs from Medaica's Henderson office but does not publish technical specifications, training data details, or performance metrics for the AI review module, and does not cite peer-reviewed validation studies.

Medaica's M1 Telehealth Stethoscope received FDA 510(k) clearance in January 2023 for over-the-counter consumer use. Per the clearance announcement, the device uses two microphones - one for cardiac and pulmonary auscultation and one for physician-patient communication - and is designed as a plug-and-play solution compatible with third-party telehealth platforms. Randall said at the time, per the company's FDA announcement: "We can make a doctor's 'digital house call' something that anyone, anywhere has access to." Medaica has reported working with Emory Hospital in Georgia and holds offices in Henderson, London, and Madrid.

A February 2026 study in European Heart Journal - Digital Health (reported by HIT Consultant Media) found that AI-enabled digital stethoscopes achieved 92.3% sensitivity detecting valvular heart disease in a 357-patient real-world trial, compared with 46.2% for traditional stethoscopes. That study covered a different device but illustrates the documented clinical case for AI-augmented auscultation as an early-screening tool. Competitors in the space include Eko Health, which has multiple FDA-cleared AI auscultation algorithms.

For practitioners: Medaica-specific published validation data for the AI review component, regulatory filings beyond the 2023 M1 clearance, EHR integration announcements, and payer coverage decisions would all be required before assessing deployability in standard care pathways.